PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma

Stopped early · Not applicable

Conditions studied: Renal Cell Carcinoma

In brief

Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical investigation of the potential role of PET perfusion imaging in management of renal carcinoma, and potentially other cancers.

Key facts

Study ID

NCT01502228

Run by

Indiana University

People needed

14

Starts

2011-10-01

Expected to finish

2014-02-01

Last updated by the study team

2019-03-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Ability to understand and willingness to sign a witnessed, informed consent and authorization for the release of health information.
• Patients with a diagnosis of relapsed Stage IV renal cell cancer that are medically unresponsive to prior treatment or surgically unresectable and with metastases that fall within the PET/CT field-of-view that can include the heart.
• Being considered for systemic therapy with Sunitinib

You may not qualify if…

• Women who are pregnant, breast-feeding, or of childbearing potential and not using birth control
• Having no telephone or a reliable way in which study personal can contact them
• Subjects who are claustrophobic and cannot tolerate imaging procedures
• Subjects who weigh > 350 lb. (upper weight limit of scanner beds)

Where it is running

• Indiana University Simon Cancer Center — Indianapolis, Indiana, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.